Phase II evaluation of diglycoaldehyde (Inox) in children with acute leukemia: a children's cancer study group report.

Abstract

A phase I trial of diglycoaldehyde (Inox) in children with leukemia established that the maximum tolerated dose of a 5-day schedule was 1.5 g/m2/day. A phase II study was undertaken by the Children's Cancer Study Group to evaluate the efficacy of this dose. Forty-seven children with acute leukemia refractory to conventional forms of therapy were entered in the study: 29 patients with acute lymphocyte leukemia/acute undifferentiated leukemia and 18 with acute nonlymphocytic leukemia. Inox was administered at a dose of 1.5 g/m2 as a 4-6 hour iv infusion daily for 5 days every 14 days. Toxic effects included myelosuppression, proteinuria, nausea, vomiting, diarrhea, local tissue reactions, hypocalcemia, transitory serum amylase elevation, and transitory hypotension. There was one life-threatening episode of drug-related renal toxicity. Of the 27 patients who received a minimum of two courses, partial remissions were observed in two patients with acute nonlymphocytic leukemia. Inox was inactive against advanced acute lymphocytic leukemia.

• Authors: G R Higgins, J Finklestein, W Krivit, D Hammond
• Journal: Cancer treatment reports (Cancer Treat Rep) 1980 Apr-May Vol. 64 Issue 4-5 Pg. 625-8 ISSN: 0361-5960 [Print] United States
• PMID: 7427952 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Aldehydes
• Antineoplastic Agents
• inosine dialdehyde
• Inosine

Topics

• Acute Disease
• Adolescent
• Adult
• Aldehydes (administration & dosage)
• Antineoplastic Agents (therapeutic use)
• Child
• Child, Preschool
• Drug Evaluation
• Female
• Humans
• Inosine (administration & dosage, analogs & derivatives)
• Kidney Diseases (chemically induced)
• Leukemia (drug therapy)
• Male